The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Understanding the concept of MGRS
Nelson Leung, MD, Mayo Clinic, Rochester, MN, discusses monoclonal gammopathy of renal significance (MGRS), a classification of B-cell or plasma-cell clonal disorders that results in kidney disease. Dr Leung highlights that clone-directed therapy is necessary for preservation of kidney function in MGRS, but that prolonged therapy is generally not required to see a response. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
MGRS is a new classification of clonal disorders that cause kidney disease. Currently we know that this can be caused by a plasma cell clone, a B-cell clone, which mostly are LPL clones and CLL clones. The main importance of the concept of MGRS is that, in these diseases, clone-directed therapy is necessary for preservation of kidney function. However, unlike in multiple myeloma, extended prolonged therapy is generally not required...
MGRS is a new classification of clonal disorders that cause kidney disease. Currently we know that this can be caused by a plasma cell clone, a B-cell clone, which mostly are LPL clones and CLL clones. The main importance of the concept of MGRS is that, in these diseases, clone-directed therapy is necessary for preservation of kidney function. However, unlike in multiple myeloma, extended prolonged therapy is generally not required. Generally, time-limited therapy is sufficient to result in renal response and a prolonged remission.
Read more...
